News

Amanta Healthcare IPO Day 1 Live: Amanta Healthcare, a pharmaceutical firm focusing on the production of parenteral products, is launching its initial public offering today (September 01) with the aim of generating ₹126 crores, and its shares are set to be listed on the NSE and BSE platforms.

Amanta Healthcare IPO price band has been set between ₹120 and ₹126 per equity share, with a face value of ₹10. Amanta Healthcare IPO includes a fresh issuance of 1 crore equity shares. 

The capital raised through the Amanta Healthcare IPO will be directed towards capital expenditures, with ₹70 crore allocated for the development of a new SteriPort manufacturing line in Hariyala, and ₹30.13 crore for the establishment of an additional line focused on SVP at the same location. The remaining funds will be utilized for general corporate needs.

Beeline Capital Advisors is acting as the primary lead manager for the book, while MUFG Intime India serves as the registrar for the offering.

Established in 1994, Amanta Healthcare focuses on the development, manufacturing, and distribution of sterile liquid formulations and medical devices.

The company's product portfolio includes IV fluids, diluents, ophthalmic solutions, items for respiratory care, irrigation solutions, and eye lubricants. Amanta utilizes cutting-edge Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies for its packaging operations.

(Stay tuned for more updates)

The financial trajectory offers both promise and caution. Amanta’s revenues moderated slightly to ₹274.7 crore in FY25 from ₹280.3 crore in FY24, but profitability surged with net profit climbing 192 per cent to ₹10.5 crore from ₹3.6 crore. Margins improved on the back of operational efficiencies, reflected in return ratios with ROE at nearly 13 per cent and ROCE above 15 per cent. Yet valuations remain demanding, with the post-issue multiple close to 47 times FY25 earnings, a steep premium over established pharmaceutical peers that typically trade in the 16–20 times range. Smaller listed competitor Denis Chem Lab, for instance, trades at nearly a third of that multiple. Analysts acknowledge Amanta’s established presence in sterile injectables, its capacity expansion, and widening distribution reach as positives that could support long-term growth. However, the elevated valuation, coupled with execution risks and sensitivity to margins in a highly competitive sector, tempers near-term enthusiasm. For investors, the offering presents a classic trade-off—expansion potential backed by solid profit momentum on one hand, and stretched pricing against sectoral averages on the other, requiring a calibrated approach rather than aggressive positioning.

— Views by Harshal Dasani, Business Head, INVasset PMS

Amanta Healthcare IPO Day 1 Live: Beeline Capital Advisors Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.

Here's how Amanta Healthcare stacks up vs its peer Denis Chem Lab:

Amanta Healthcare IPO Day 1 Live: Amanta Healthcare IPO sailed through in a little over an hour. The retail portion was subscribed 1.64 times, the NII portion was booked 0.88 times and the QIB portion was not yet off the mark.

The company plans to use the funds raised for the following:

Amanta Healthcare IPO Day 1 Live: Here are key details of the IPO at a glance:

Face Value: ₹10 per share

Price Band: ₹120 to ₹126 per share

Issue Type: Fresh Capital

Total Issue Size: ₹126 crores

Lot Size: 119 shares per lot

Amanta Healthcare IPO Day 1 Live: Amanta Healthcare IPO was subscribed 25% in just 15 minutes of opening, with bidding led by retail investors and NIIs. The retail portion was booked 40% and the NII segment was subscribed 27%. QIB portion was at nil.

Amanta Healthcare IPO Day 1 Live: Amanta Healthcare IPO kicked off for bidding on Monday. Investors can apply for the IPO till 5 pm. The issues will close for bidding on Wednesday

The issue is valued at a P/E ratio of 46.6x based on FY25 PAT. Strengths such as an experienced promoter, established market position, large distributor network, and proposed capacity expansion plans along with a diverse product profile are offset by a high debt-to-equity ratio, exposure to intense competition, and susceptibility of operating margins to volatility in packing material prices.

We recommend a ‘May Subscribe’ to this issue.

— Views by Minerva Capital

Amanta Healthcare secured ₹37.80 crore through its anchor book process on August 29, 2025. According to the exchange filing, six investors participated in the anchor book offering.

Here's the list:

1. Bandhan Small Cap Fund

2. Sanshi Fund-1

3. Perpetuity Health to Wealth (H2W) Rising Fund

4. Aarth Growth Fund

5. Sunrise Investment Trust- Sunrise Investment Opportunities Fund

6. Finavenue Capital Trust- Finavenue Growth Fund

Amanta Healthcare Limited has allocated a total of 30,00,000Equity Shares to these anchor investors, with each share priced at ₹ 126.

Amanta Healthcare IPO GMP today or grey market premium is +28. This indicates Amanta Healthcare share price were trading at a premium of ₹28 in the grey market on Monday, according to investorgain.com.

Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Amanta Healthcare share price was indicated at ₹154 apiece, which is 22.22% higher than the IPO price of ₹126 .

Based on the grey market trends from the last ten sessions, today's IPO GMP shows an upward trend and anticipates a solid listing. The minimum GMP recorded is ₹0.00, whereas the maximum is ₹28, according to experts.

'Grey market premium' indicates investors' readiness to pay more than the issue price.

Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.

Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

Download the Mint app and read premium stories

Log in to our website to save your bookmarks. It'll just take a moment.